Cargando…

Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort

Large healthcare administrative databases, like Medicare claims, are a common means to evaluate drug policies. However, administrative data often have a lag time of months to years before they are available to researchers and decision-makers. Therefore, administrative data are not always ideal for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayes, Kaleen N., Mor, Vincent, Zullo, Andrew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114471/
https://www.ncbi.nlm.nih.gov/pubmed/35600866
http://dx.doi.org/10.3389/fphar.2022.855598
_version_ 1784709782436839424
author Hayes, Kaleen N.
Mor, Vincent
Zullo, Andrew R.
author_facet Hayes, Kaleen N.
Mor, Vincent
Zullo, Andrew R.
author_sort Hayes, Kaleen N.
collection PubMed
description Large healthcare administrative databases, like Medicare claims, are a common means to evaluate drug policies. However, administrative data often have a lag time of months to years before they are available to researchers and decision-makers. Therefore, administrative data are not always ideal for timely policy evaluations. Other sources of data are needed to rapidly evaluate policy changes and inform subsequent studies that utilize large administrative data once available. An emerging area of interest in both pharmacoepidemiology and drug policy research that can benefit from rapid data availability is biosimilar uptake, due to the potential for substantial cost savings. To respond to the need for such a data source, we established a public-private partnership to create a near-real-time database of over 1,000 nursing homes’ electronic health records to describe and quantify the effects of recent policies related to COVID-19 and medications. In this article, we first describe the components and infrastructure used to create our EHR database. Then, we provide an example that illustrates the use of this database by describing the uptake of insulin glargine-yfgn, a new exchangeable biosimilar for insulin glargine, in US nursing homes. We also examine the uptake of all biosimilars in nursing homes before and after the onset of the COVID-19 pandemic. We conclude with potential directions for future research and database infrastructure.
format Online
Article
Text
id pubmed-9114471
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91144712022-05-19 Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort Hayes, Kaleen N. Mor, Vincent Zullo, Andrew R. Front Pharmacol Pharmacology Large healthcare administrative databases, like Medicare claims, are a common means to evaluate drug policies. However, administrative data often have a lag time of months to years before they are available to researchers and decision-makers. Therefore, administrative data are not always ideal for timely policy evaluations. Other sources of data are needed to rapidly evaluate policy changes and inform subsequent studies that utilize large administrative data once available. An emerging area of interest in both pharmacoepidemiology and drug policy research that can benefit from rapid data availability is biosimilar uptake, due to the potential for substantial cost savings. To respond to the need for such a data source, we established a public-private partnership to create a near-real-time database of over 1,000 nursing homes’ electronic health records to describe and quantify the effects of recent policies related to COVID-19 and medications. In this article, we first describe the components and infrastructure used to create our EHR database. Then, we provide an example that illustrates the use of this database by describing the uptake of insulin glargine-yfgn, a new exchangeable biosimilar for insulin glargine, in US nursing homes. We also examine the uptake of all biosimilars in nursing homes before and after the onset of the COVID-19 pandemic. We conclude with potential directions for future research and database infrastructure. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9114471/ /pubmed/35600866 http://dx.doi.org/10.3389/fphar.2022.855598 Text en Copyright © 2022 Hayes, Mor and Zullo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hayes, Kaleen N.
Mor, Vincent
Zullo, Andrew R.
Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
title Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
title_full Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
title_fullStr Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
title_full_unstemmed Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
title_short Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
title_sort electronic health records to rapidly assess biosimilar uptake: an example using insulin glargine in a large u.s. nursing home cohort
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114471/
https://www.ncbi.nlm.nih.gov/pubmed/35600866
http://dx.doi.org/10.3389/fphar.2022.855598
work_keys_str_mv AT hayeskaleenn electronichealthrecordstorapidlyassessbiosimilaruptakeanexampleusinginsulinglargineinalargeusnursinghomecohort
AT morvincent electronichealthrecordstorapidlyassessbiosimilaruptakeanexampleusinginsulinglargineinalargeusnursinghomecohort
AT zulloandrewr electronichealthrecordstorapidlyassessbiosimilaruptakeanexampleusinginsulinglargineinalargeusnursinghomecohort